According to IMARC Group latest report titled “Biopharmaceutical Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032”, offers a comprehensive analysis of the industry, which comprises insights on biopharmaceutical market growth. The report also includes competitor and regional analysis, and contemporary advancements in the global market.
The global biopharmaceutical market size reached US$ 300.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 643.9 Billion by 2032, exhibiting a growth rate (CAGR) of 8.6% during 2024-2032.
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA, or antisense oligonucleotides) used for therapeutic or in vivo diagnostic purposes, and are produced by means other than direct extraction from a native (non-engineered) biological source. The defining characteristics of biopharmaceuticals are their complex, large molecule structures and their ability to target specific physiological processes with a high degree of efficacy. This specificity reduces the risk of side effects typically associated with traditional pharmaceuticals. The working mechanism of biopharmaceuticals involves interacting with the body’s natural processes to treat or prevent diseases, often by targeting specific cellular or genetic components. The properties of biopharmaceuticals, like stability and delivery methods, are optimized through advanced technologies. The advantages of biopharmaceuticals include their ability to address previously untreatable conditions, offer personalized treatment options, and reduce overall healthcare costs by improving treatment outcomes.
Get a Sample Copy of this Report: https://www.imarcgroup.com/biotechnology-industry/requestsample
Market Trends:
The global market is primarily propelled by the escalating prevalence of chronic diseases worldwide. This increase in disease incidence is closely linked with the aging global population, which brings a higher demand for effective treatment options. In addition, the market is receiving a significant boost from the rapid advancements in biotechnology research and development. These advancements are enabling the creation of more effective and targeted therapies. Furthermore, the increasing investment in healthcare infrastructure, particularly in emerging economies, is facilitating access to advanced biopharmaceutical treatments. In parallel, the growing awareness and acceptance of biopharmaceuticals over conventional drugs is another key driver, as patients and healthcare providers seek out more efficient treatment modalities with fewer side effects.
The expanding scope of biopharmaceutical applications, including the development of personalized medicine, is also playing a critical role in market growth. Moreover, favorable government policies and regulatory support, aimed at promoting innovation and ensuring the safety and efficacy of biopharmaceutical products, are encouraging investments in this sector. The market is further reinforced by strategic collaborations and partnerships among key players, fostering innovation and expansion of product portfolios. Additionally, the increasing prevalence of lifestyle-related diseases, coupled with the rising focus on preventive healthcare, is promoting the use of biopharmaceuticals. The market is also benefiting from the growing trend of patent expirations of major biopharmaceuticals, opening opportunities for biosimilars.
View Full Report with TOC & List of Figure: https://www.imarcgroup.com/biotechnology-industry
Competitive Landscape:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
- AbbVie Inc.
- Amgen Inc
- Biogen Inc.
- Eli Lilly and Company
- Hoffmann-La Roche AG
- Johnson & Johnson
- Merck & Co. Inc.
- Novo Nordisk A/S
- Pfizer Inc.
- Sanofi S.A
Biopharmaceutical Market Segmentation:
Our report has categorized the market based on regions, indication and class.
Breakup by Indication:
- Autoimmune diseases
- Oncology
- Metabolic disorders
- Others
Breakup by Class:
- Recombinant Proteins
- Monoclonal Antibodies
- Purified Proteins
Breakup by Region:
- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
Key highlights of the report:
- Market Performance (2018-2023)
- Market Outlook (2024-2032)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
Comments